The Oncology H1 2025 Landscape Review

Expert insights into the trends shaping the oncology drug development landscape in H1 2025. Discover the top targets and therapeutic streams of newly released assets, the leading disease indications studied in clinical trials, investment patterns and the highest-value commercial targets, as well as the companies spearheading the greatest number of newly disclosed assets.

The Oncology Drug Development Landscape

Download this critical review to receive a data-driven analysis of the Oncology drug, trial and commercial landscape. Put yourself at the forefront of innovation with unparalleled insights into the dynamic and fast-paced world of Oncology drug development with Beacon Oncology.

Download Now

 

This Review Contains Key Insight Into:

  • New Drugs by Therapeutic Stream: Biologics have dominated new assets disclosed in H1 2025 for the treatment of Oncology disease indications. ADCs continue to show rapid growth, with a 54% increase in preclinical assets transitioning into the clinic.
  • Drugs by Target and Therapeutic Class: CD3 is the most popular target for Oncology drug developers, being a prominent target for Bispecifics, while KRAS has shown activity for small molecule therapies, specifically PROTACs.
  • Trials by Disease Indication: The number of clinical trials has increased across blood cancer and solid tumors in H1 2025, with Bowel Cancer having the greatest percentage increase.
  • Investment trends: PD-1 was the most commercially attractive target, with 12 deals in H1 2025, while CLDN18.2 experienced the largest increase in deals compared to 2024.
  • Company Highlights: Discover the companies leading the way for new drug assets disclosed. Chinese-based biotechs are making significant advances within the biological therapies market, across ADC and Bispecific

Download Now

You May Also Be Interested In…

Learn More About Oncology

What is Beacon Oncology?
  • The Most Comprehensive Way to Search the Oncology Drug Development Landscape: Unique search ontologies based on Oncology drug and trial characteristics
  • Market Leading Approach to Oncology Preclinical & Clinical Data Curation: Manual curation of key Oncology research and development data points by Oncology research scientists
  • Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Oncology company and deal data based on their pipeline and technologies.
  • Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
Learn More About Beacon Oncology

What is Beacon?

Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more

Menu
Search Icon
Close Icon
Search